Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL170728 | 0.86 | ACHE (0.46) | TAAR1KDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL14671415 | 0.85 | SMN1; SMN2 (0.46) | TAAR1KDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL15302783 | 0.84 | TAAR1 (0.38) | TAAR1KDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL15618222 | 0.84 | ALDH1A1 (0.41) | TAAR1KDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL27660692 | 0.84 | TAAR1 (0.39) | TAAR1KDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL172572 | 0.84 | TAAR1 (0.38) | TAAR1KDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL9189975 | 0.84 | TAAR1 (0.42) | TAAR1KDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL7706281 | 0.84 | TAAR1 (0.38) | TAAR1KDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL13228082 | 0.84 | TAAR1 (0.68) | TAAR1KDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL19446544 | 0.84 | GABRA1 (0.41) | TAAR1KDM4EALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| WO-2023170024-A1 | CAMK2 MODULATORS AND THEIR USE IN MEDICINE | UNIVERSITY OF COPENHAGEN (DK) | 2023-09-14 | — | — | WO | disclosed |
| EP-4234565-A2 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | ATEA Pharmaceuticals, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20220169621-A1 | OXADIAZOLES FOR USE IN CONTROLLING PHYTOPATHOGENIC FUNGI | PI INDUSTRIES LTD. (IN) | 2022-06-02 | — | — | US | disclosed |
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-04-28 | — | — | US | disclosed |
| US-11225480-B2 | Malic enzyme inhibitors | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-01-18 | — | — | US | disclosed |
| EP-3313396-B1 | G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME | UNIV MICHIGAN REGENTS (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-2968211-B1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO PHARM SOLUTIONS CO LTD (KR) | 2021-05-12 | — | — | EP | disclosed |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2021-04-22 | — | — | US | disclosed |
| US-20090306112-A1 | ANTIVIRAL PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| EP-2116522-A1 | PENTACYCLIC LIQUID CRYSTAL COMPOUND HAVING CF<SB>2</SB>O BONDING GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY | Chisso Corporation (JP) | 2009-11-11 | — | — | EP | disclosed |
| EP-2070928-A1 | 7-azaindol-3-ylacrylamides active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2009-06-17 | — | — | EP | disclosed |
| US-20090105279-A1 | Antiviral protease inhibitors | GILEAD SCIENCES, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090099096-A1 | AZA-peptide protease inhibitors | GILEAD SCIENCES, INC. | 2009-04-16 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-31 | — | — | US | disclosed |
| US-7271270-B2 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| WO-2004024728-A2 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, CYP4F11, WEE1 | TAAR1 4796/4885KDM4E 3806/4885ALDH1A1 401/4885 |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | TAAR1 4603/4885KDM4E 1301/4885ALDH1A1 144/4885 |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | TRPV1, KCNJ2, KCNN3 | TAAR1 2280/4885KDM4E 2958/4885ALDH1A1 1645/4885 |
| US-20090105279-A1 | Antiviral protease inhibitors | ACE, TMPRSS15, MME | TAAR1 4724/4885KDM4E 1726/4885ALDH1A1 3629/4885 |
| US-11225480-B2 | Malic enzyme inhibitors | ME1, RNASE1, ME2 | TAAR1 3983/4885KDM4E 821/4885ALDH1A1 89/4885 |
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | TAAR1 4603/4885KDM4E 1301/4885ALDH1A1 144/4885 |
| US-11813278-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | TAAR1 4601/4885KDM4E 3971/4885ALDH1A1 2718/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | TAAR1 2374/4885KDM4E 3026/4885ALDH1A1 148/4885 |
| US-20090099096-A1 | AZA-peptide protease inhibitors | DNPEP, ANPEP, PEPD | TAAR1 4128/4885KDM4E 515/4885ALDH1A1 4015/4885 |
| US-20090306112-A1 | ANTIVIRAL PROTEASE INHIBITORS | ACE, DNPEP, TMPRSS15 | TAAR1 4736/4885KDM4E 1704/4885ALDH1A1 3653/4885 |
| US-20220169621-A1 | OXADIAZOLES FOR USE IN CONTROLLING PHYTOPATHOGENIC FUNGI | OXA1L, CYP51A1, CYP1A1 | TAAR1 1247/4885KDM4E 2671/4885ALDH1A1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.